Showing results (151-160 of 192) with videos related to

Sort By:
Pageof 20
Journal of Gastroenterology|September 17, 2015
Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective studyTatsuo Inoue, Tomoko Hyodo, Keiko Korenaga, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|September 30, 2020
Intraprocedurally EOB-MRI/US fusion imaging focusing on hepatobiliary phase findings can help to reduce the recurrence of hepatocellular carcinoma after radiofrequency ablationFeiqian Wang, Kazushi Numata, Hiromi Nihonmatsu, et al.
The Lancet. Gastroenterology & Hepatology|May 13, 2017
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trialMasatoshi Kudo, Michihisa Moriguchi, Kazushi Numata, et al.
Journal of Digestive Diseases|December 16, 2014
Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weightingMasaaki Kondo, Manabu Morimoto, Tomohiro Ishii, et al.
Liver Cancer|October 9, 2025
Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT StudyMasatoshi Kudo, Kazuomi Ueshima, Kaoru Tsuchiya, et al.
Diagnostics (Basel, Switzerland)|January 25, 2025
Diagnostic Accuracy of Detective Flow Imaging Endoscopic Ultrasonography for Evaluating Blood Flow Within Mural Nodules of Intraductal Papillary Mucinous NeoplasmsKazuki Endo, Haruo Miwa, Kazuya Sugimori, et al.
BMC Cancer|October 17, 2019
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trialMasaaki Kondo, Manabu Morimoto, Satoshi Kobayashi, et al.
Liver Cancer|August 20, 2025
First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 TrialMasatoshi Kudo, Masafumi Ikeda, Hiroshi Aikata, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|January 24, 2022
Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world settingTaito Fukushima, Manabu Morimoto, Makoto Ueno, et al.
The Oncologist|April 6, 2023
Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus BevacizumabTaito Fukushima, Manabu Morimoto, Satoshi Kobayashi, et al.
Pageof 20